source
- Pharma access plans rise to 69% of late-stage drugs but gaps remain for non-communicable diseasesA new analysis shows that many large drug makers are expanding programs to make medicines available in low- and middle‑income markets, but progress is uneven across disease areas. Access plans now…
- PepGen reports promising early results for myotonic dystrophy type 1 drug in six-patient trialPepGen announced that its experimental therapy for myotonic dystrophy type 1 showed the most encouraging early data yet in a small study. The trial involved six patients who received the drug for 1…